Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Vitamin K3H2. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.50 |
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vitamin K3H2 SCHEMBL28664356 | 1.00 | HTT (0.81) | HTTLMNAPKMMAPTKDM4E | |
| Vitamin K3H2 SCHEMBL29525544 | 0.90 | HTT (1.00) | HTTLMNAPKMMAPTKDM4E | |
| Vitamin K3H2 SCHEMBL297164 | 0.90 | HTT (1.00) | HTTLMNAPKMMAPTKDM4E | |
| Vitamin K3H2 SCHEMBL2887680 | 0.88 | HTT (0.95) | HTTLMNAPKMMAPTKDM4E | |
| Vitamin K3H2 SCHEMBL515182 | 0.85 | HTT (0.81) | HTTLMNAPKMMAPTKDM4E | |
| Vitamin K3H2 SCHEMBL5075246 | 0.85 | HTT (0.81) | HTTLMNAPKMMAPTKDM4E | |
| Vitamin K3H2 SCHEMBL515420 | 0.85 | HTT (0.81) | HTTLMNAPKMMAPTKDM4E | |
| Vitamin K3H2 SCHEMBL27560223 | 0.83 | HTT (0.78) | HTTLMNAPKMMAPTKDM4E | |
| SCHEMBL13811025 | 0.81 | HTT (0.63) | HTTLMNAPKMMAPTKDM4E | |
| Vitamin K3H2 SCHEMBL987810 | 0.81 | HTT (0.75) | HTTLMNAPKMMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212214-B2 | Methods of increasing the expression yield of vitamin K-dependent proteins | CSL LIMITED (AU) | 2015-12-15 | — | — | US | claimed |
| JP-2010540159-A | — | — | 2010-12-24 | — | — | JP | claimed |
| JP-2010509991-A | — | — | 2010-04-02 | — | — | JP | claimed |
| EP-2086602-A2 | DRUG RELEASING COATINGS FOR MEDICAL DEVICES | Lutonix, Inc. (US) | 2009-08-12 | — | — | EP | claimed |
| EP-2073860-A1 | DRUG RELEASING COATINGS FOR MEDICAL DEVICES | Lutonix, Inc. (US) | 2009-07-01 | — | — | EP | claimed |
| EP-2066321-A2 | TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH ANTI-PROLIFERATE AND ANTI-INFLAMMATORY DRUGS | Lutonix, Inc. (US) | 2009-06-10 | — | — | EP | claimed |
| WO-2009051614-A1 | DRUG RELEASING COATINGS FOR MEDICAL DEVICES | LUTONIX, INC. (US) | 2009-04-23 | — | — | WO | claimed |
| US-20080255508-A1 | Such as balloon and stents; medical device with overcoating of drug with additive; bioavailability | LUTONIX, INC. | 2008-10-16 | — | — | US | claimed |
| US-20080175887-A1 | drug delivering by oral, nasal or pulmonary administration, of rapamycin or paclitaxel drug; additive enhances absorption of drug into body tissue; PEG-fatty acids esters, PEG-fatty alcohol ethers, polyethylene glycol sorbitan fatty acid esters, polyoxyethylene-polyoxypropylene block copolymers | LUTONIX, INC. | 2008-07-24 | — | — | US | claimed |
| WO-2008063581-A2 | TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH ANTI-PROLIFERATE AND ANTI-INFLAMMATORY DRUGS | LUTONIX, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| WO-2008063576-A2 | DRUG RELEASING COATINGS FOR MEDICAL DEVICES | LUTONIX, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| US-20080118544-A1 | Such as a balloon catheter or a stent; a drug not enclosed in micelles or encapsulated in particles or controlled release carriers and an additive having hydrophobic and hydrophilic portions; improved pharmacokinetics and bioavailability | LUTONIX, INC. | 2008-05-22 | — | — | US | claimed |
| EP-4223352-B1 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | UROTRONIC INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12611398-B2 | Inhalable rapamycin formulation for the treatment of pulmonary hypertension | ORPHAI THERAPEUTICS INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12605342-B2 | Polymer-encapsulated drug particles | TONIC MEDICAL, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12576037-B2 | Polymer-encapsulated drug particles | TONIC MEDICAL, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-5763479-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIS AGENTS | KS BIOMEDIX LTD. (GB) | 1998-06-09 | — | — | US | disclosed |
| EP-0570414-A1 | NAPHTHOQUINONE DERIVATIVES FOR THE TREATMENT OF CHRONIC INFLAMMATION | KS BIOMEDIX LTD. (GB) | 1993-11-24 | — | — | EP | disclosed |
| WO-1992013532-A2 | NAPHTHOQUINONE DERIVATIVES FOR THE TREATMENT OF CHRONIC INFLAMMATION | CHAYEN JOSEPH (GB) | 1992-08-20 | — | — | WO | disclosed |
| US-5116406-A | Choline chloride and vitamin k | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1992-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576037-B2 | Polymer-encapsulated drug particles | PHOSPHO1, SGMS1, SGMS2 | HTT 3683/4885LMNA 1040/4885PKM 2391/4885 |
| US-12605342-B2 | Polymer-encapsulated drug particles | MUC1, SLC10A2, EGFR | HTT 2824/4885LMNA 2541/4885PKM 2084/4885 |
| US-12611398-B2 | Inhalable rapamycin formulation for the treatment of pulmonary hypertension | RICTOR, MTOR, RPTOR | HTT 800/4885LMNA 1497/4885PKM 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.